Genmab - Tisotumab Vedotin
Tisotumab Vedotin is an antibody-drug conjugate (ADC) targeted to tissue factor (TF), a protein involved in tumor signaling and angiogenesis.1 It is composed of Genmab’s human monoclonal antibody (mAb) that binds to TF and Seagen’s ADC technology that utilizes a cleavable linker and the cytotoxic drug monomethyl auristatin E (MMAE).1 TF is a transmembrane protein that is the main physiological initiator of coagulation and is involved in angiogenesis, cell adhesion, motility, and cell survival.2,3 The presence of TF is associated with poor prognosis.
Details
Indication and Safety
The U.S. FDA granted accelerated approval for Tivdak® (Tisotumab Vedotin-tftv) for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.
Customer reviews
No reviews were found for Genmab - Tisotumab Vedotin. Be the first to review!